# This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

> **NCT07121946** · PHASE1 · RECRUITING · sponsor: **LTZ Therapeutics, Inc.** · enrollment: 42 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma Refractory/ Relapsed
- DLBCL - Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma (MCL)
- Follicular Lymphoma ( FL)
- Marginal Zone Lymphoma (MZL)

## Interventions

- **BIOLOGICAL:** LTZ-301
- **BIOLOGICAL:** LTZ-301
- **BIOLOGICAL:** LTZ-301

## Key facts

- **NCT ID:** NCT07121946
- **Lead sponsor:** LTZ Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07121946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07121946, "This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07121946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*